CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events

Item 8.01.Other Events.

On June 29, 2017, CytomX Therapeutics, Inc. issued a press
release announcing that the company has advanced CX-2029, a
Probody drug conjugate (PDC) targeting CD71 and being developed
in collaboration with AbbVie, into GLP toxicology studies. Upon
commencement of the GLP toxicology study, CytomX will receive a
$15 million milestone payment from AbbVie as part of the 2016
strategic oncology collaboration between the companies. The full
text of the press release is furnished as Exhibit 99.1 hereto.

Reference is made to the Exhibit Index attached hereto

CytomX Therapeutics, Inc. Exhibit
EX-99.1 2 ctmx-ex991_6.htm EX-99.1 ctmx-ex991_6.htm EXHIBIT 99.1     CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate     SOUTH SAN FRANCISCO,…
To view the full exhibit click here
About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.